Findings from the IDEAL-LM (Improved Drug Eluting Stent for All-comer Left Main) trial, presented at Transcatheter Cardiovascular Therapeutics (TCT) 2019 by co-principal investigator Robert-Jan M. van Geuns, MD, PhD, of Radboud University Medical Center, Nijmegen, Netherlands, demonstrate that a biodegradable-polymer everolimus-eluting stent followed by only four months of dual antiplatelet therapy (DAPT) was non-inferior to a durable-polymer everolimus-eluting stent followed by 12 months of DAPT.